Related Experiment Video
Updated: Aug 14, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir
Laura B Talarico1, Viviana Castilla, Javier A Ramirez
1Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina.
Abstract:
The replication of herpes simplex virus (HSV) type 1 in Vero cells is inhibited in the presence of (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (6b), a synthetic brassinosteroid derivative. Since a late step of virus multiplication is hindered by 6b, we performed studies of drug-drug combination with acyclovir (ACV) and foscarnet (FOS). It was determined that 6b would act synergistically with low concentrations of ACV and moderate concentrations of FOS against HSV. The best drug combination tested in this study resulted in an increase of 29.3 and 47.2% in antiviral activity for ACV (0.036 microM) and FOS (37.5 microM) in the presence of 14.8 and 6.9 microM of 6b, respectively.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Herpes
Genital Herpes
DNA Base Pairing
Inhibitors of Viral Protein Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...

